As #WorldAMRAwarenessWeek comes to an end, we’re spotlighting the urgent need to improve access to antibiotics in lower-income countries. Through our collaboration with the Global Antibiotic R&D Partnership (GARDP), we’re helping strengthen access where the burden of antimicrobial resistance (#AMR) is greatest and resources are often most limited. In 2024, we committed €4.5 million to GARDP, and we’ve already made meaningful progress. Together, we’re deepening our understanding of how people access antibiotics and exploring innovative ways to bring both new and existing treatments to market. Hear from GSK’s Chief Global Health Officer, Thomas Breuer, MD, MSc, and Executive Director of GARDP, Dr Manica Balasegaram, as they discuss the realities of AMR in lower-income countries and why cross-sector collaboration is essential to tackling this global health challenge.